1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  11:36 2022-06-24 am EDT
1.195 EUR   -1.65%
06/09Biofrontera AG Appoints Paul Böckmann to Management Board
CI
06/08PTA-NEWS : Biofrontera AG: Biofrontera's license partner Louis Widmer receives an extension of its marketing authorization for Ameluz®
PU
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/20/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
1.17(c) 1.19(c) 1.2(c) 1.215(c) 1.195(c) Last
17 694 1 000 8 900 1 400 2 300 Volume
-8.24% +1.71% +0.84% +1.25% -1.65% Change
More quotes
Estimated financial data (e)
Sales 2022 35,7 M 37,7 M 37,7 M
Net income 2022 -29,0 M -30,6 M -30,6 M
Net Debt 2022 - - -
P/E ratio 2022 -2,66x
Yield 2022 -
Sales 2023 34,8 M 36,7 M 36,7 M
Net income 2023 2,00 M 2,11 M 2,11 M
Net Debt 2023 - - -
P/E ratio 2023 39,8x
Yield 2023 -
Capitalization 67,8 M 71,5 M 71,5 M
Capi. / Sales 2022 1,90x
Capi. / Sales 2023 1,95x
Nbr of Employees 95
Free-Float 43,4%
More Financials
Company
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells;... 
Sector
Pharmaceuticals
Calendar
09/01Earnings Release
More about the company
Ratings of Biofrontera AG
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOFRONTERA AG
06/09Biofrontera AG Appoints Paul Böckmann to Management Board
CI
06/08PTA-NEWS : Biofrontera AG: Biofrontera's license partner Louis Widmer receives an extensio..
PU
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
05/17Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT
05/02TRANSCRIPT : Biofrontera AG, 2021 Earnings Call, May 02, 2022
CI
04/30Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/30PTA-NEWS : Biofrontera AG: Biofrontera reports results for the fiscal year 2021
PU
04/29Biofrontera AG Provides Earnings Guidance for the Year 2022
CI
04/28PTA-NEWS : Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to..
PU
04/14PTA-NEWS : Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2..
PU
04/13Top Midday Gainers
MT
04/13Biofrontera Shares Jump 31% After FDA Approves Contract Laboratory for Ameluz
DJ
04/13Biofrontera Says FDA Has Approved German Facility as Contract Laboratory for Testing of..
MT
04/13Biofrontera Shares Halted After FDA Approves German Lab for Testing Ameluz
DJ
More news
News in other languages on BIOFRONTERA AG
06/09Biofrontera AG nomme Paul Böckmann au conseil d'administration
05/17NACHBÖRSE/XDAX +0,4% auf 14.237 Pkt - Tui-Aktie unter Druck
05/17Biofrontera AG annonce ses résultats pour le premier trimestre se terminant le 31 mars ..
05/13Earnings Flash (BFRI) BIOFRONTERA affiche un chiffre d'affaires de 9,8 millions de doll..
04/30Biofrontera AG annonce ses résultats pour l'année complète se terminant le 31 décembre ..
More news
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,20 €
Average target price 3,35 €
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Ludwig Lutter Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-17.91%72
CSL LIMITED-7.99%89 014
SAMSUNG BIOLOGICS CO.,LTD.-7.97%44 870
WUXI BIOLOGICS (CAYMAN) INC.-24.42%37 601
BIOGEN INC.-11.90%30 316
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.19%23 626